EGFR and non-small cell lung carcinoma: In the past decade, the epidermal growth factor receptor (EGFR)-targeting tyrosine kinase inhibitors (TKIs) such as gefitinib and erlotinib have shown remarkable benefits in all stages of NSCLC patients with drug-sensitive mutations in the EGFR gene [3, 4].